ALTRAVAX, INC.
Universal influenza B vaccine based on engineered hemagglutinin variants with cross-lineage activity
- Sector
- Biotech
- Headquarters
- Rochester, MN
- Founded
- 2009
- Latest Form D
- $2M, Nov 2009
- Total capital
- $3.4M
- Federal grants
- $1.4M
- 4 awards · 2015
- Rank in peer group#202 of 326
- Private capital raised
- $2M
- 2 Form D · last Nov 2009
- 203 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 3 pending · first 2016
- Rank in peer group#80 of 326
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Development of a Universal Influenza B Vaccine$300K
- Federal grantHealth and Human S · Phase I · Novel Subunit Vaccines against Varicella Zoster Virus$297K
- Federal grantHealth and Human S · Phase I · Development of a Universal Influenza B Vaccine$300K
- Federal grantHealth and Human S · Phase I · A Protective Tetravalent Vaccine Candidate for Dengue Fever Virus$533K
- Private capital raisedForm D · SEC · 2nd filing$2M
- Private capital raisedForm D · SEC · 1st filing$7K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#80 · top 25%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Robert E. WhalenResearcherPromoterLinked by $597K in grants as PI
- James E. BurgumDirectorNamed in SEC Form D filings
- Leonard P RuizExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Michael E ChambersDirector, PromoterNamed in SEC Form D filings
- Ronald E. BerganDirectorNamed in SEC Form D filings
- Scott E. RosenowExecutive Officer, PromoterNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 4- PendingHepatitis B Virus VaccinesUSPTOApplication 15138647
- PendingNovel Flavivirus AntigensUSPTOApplication 14942079
- GrantedHepatitis B Virus VaccinesUSPTOUS 9,353,158
Show all 4 patent records
- Hepatitis B Virus VaccinesAug 11, 2016 · Application 15138647Pending
- Novel Flavivirus AntigensJun 2, 2016 · Application 14942079Pending
- Hepatitis B Virus VaccinesMay 31, 2016 · US 9,353,158Granted
- Hepatitis B Virus VaccinesApplication PCTUS2014024882Pending
Related companies, and why
- ModernaSimilar federal contract value in Biotech · null in contracts
- Mariana OncologySimilar federal contract value in Biotech · null in contracts
- Denali TherapeuticsSimilar federal contract value in Biotech · null in contracts
- MS Biotech Holdings, Inc.Similar federal contract value in Biotech · null in contracts
- PROLACTA BIOSCIENCE INCSimilar federal contract value in Biotech · null in contracts
- CalciMedica Subsidiary, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .